铂类时代I期子宫内膜样或透明细胞卵巢癌辅助化疗的SEER队列研究
基于SEER数据库2000-2013年I期子宫内膜样卵巢癌(EEOC)3552例和卵巢透明细胞癌(OCCC)1995例,评估辅助化疗对总生存(OS)的影响。EEOC中化疗组5年OS率90% vs 未化疗组89%(P=0.807),OCCC中85% vs 83%(P=0.439),均无显著差异。仅FIGO IC期、3级EEOC亚组(n=282)化疗与5年OS改善相关:81% vs 62%(P=0.003;HR 0.583;95%CI 0.359-0.949;P=0.030)。OCCC任何亚期均无显著OS获益。
要点
- I期EEOC总体辅助化疗与未化疗5年OS率无显著差异(90% vs 89%,P=0.807)。
- I期OCCC总体辅助化疗与未化疗5年OS率无显著差异(85% vs 83%,P=0.439)。
- 仅IC期3级EEOC亚组化疗与5年OS改善相关(81% vs 62%,P=0.003;HR 0.583)。
核心结论
- 辅助化疗仅与FIGO IC期、3级EEOC患者OS改善相关。
- I期OCCC中辅助化疗与OS改善无关。
研究设计与样本
- SEER数据库队列研究,纳入2000-2013年FIGO I期EEOC 3552例和OCCC 1995例。
- 采用log-rank检验和Cox比例风险模型比较OS,并分析化疗使用的预测因素。
主要发现
- EEOC中1600例(45%)接受辅助化疗,5年OS率90% vs 未化疗组89%(P=0.807)。
- OCCC中1374例(69%)接受辅助化疗,5年OS率85% vs 未化疗组83%(P=0.439)。
- 两组中化疗使用均与较年轻年龄、较高亚期和较近诊断年份相关。
- IC期3级EEOC亚组(n=282)化疗组5年OS率81% vs 未化疗组62%(P=0.003;HR 0.583;95%CI 0.359-0.949;P=0.030)。
- OCCC任何亚期均未见辅助化疗对OS的显著影响。
临床怎么用
- 对于I期EEOC和OCCC,辅助化疗的决策需结合亚期和分级,尤其IC期3级EEOC可能从化疗中获益。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We sought to evaluate the impact of adjuvant chemotherapy on overall survival (OS) in patients with stage I endometrioid epithelial ovarian cancer (EEOC) or ovarian clear cell cancer (OCCC) using a national database. PATIENTS AND METHODS: The Surveillance, Epidemiology, and End Results database was used to identify patients diagnosed with International Federation of Gynecology and Obstetrics (FIGO) stage I EEOC or OCCC from 2000 to 2013. We sought to identify predictors of chemotherapy use and to assess the impact of chemotherapy on OS in these patients. OS was compared using the log-rank test and the Cox proportional hazards model. RESULTS: In all, 3552 patients with FIGO stage I EEOC and 1995 patients with stage I OCCC were identified. Of the 1600 patients (45%) with EEOC who underwent adjuvant chemotherapy, the 5-year OS rate was 90%, compared with 89% for those who did not undergo adjuvant chemotherapy (P = 0.807). Of the 1374 (69%) patients with OCCC who underwent adjuvant chemotherapy, the 5-year OS rate was 85%, compared with 83% (P = 0.439) for those who did not undergo adjuvant chemotherapy. Chemotherapy use was associated with younger age, higher substage, and more recent year of diagnosis for both the EEOC and OCCC groups. Only in the subgroup of patients with FIGO substage IC, grade 3 EEOC (n = 282) was chemotherapy associated with an improved 5-year OS-81% compared with 62% (P = 0.003) in untreated patients (HR: 0.583; 95% CI: 0.359-0.949; P = 0.030). In patients with OCCC, there was no significant effect of adjuvant chemotherapy on OS in any substage. CONCLUSIONS: Adjuvant chemotherapy was associated with improved OS only in patients with substage IC, grade 3 EEOC. In stage I OCCC, adjuvant chemotherapy was not associated with improved OS.
引用
- Oseledchyk A, Leitao MM, Konner J, et al. Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a Surveillance, Epidemiology, and End Results Cohort Study, 2000-2013. Ann Oncol. 2017. PMID: 28950307. doi:10.1093/annonc/mdx525
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。